November 4, 2026

Subscribe
Fitness startups are raising again, but investors have stopped funding the treadmill

Fitness startups are raising again, but investors have stopped funding the treadmill

by | Aug 21, 2026 | Fitness & Movement

The rebound in wellness funding is real. What's actually getting funded inside it has changed completely.

Fitness and wellness startup funding is recovering after a rough stretch. The companies actually capturing that recovery look nothing like the hardware-first fitness startups that defined the category five years ago.

WHAT HAPPENED

The rebound is concentrated in data, not equipment

Alongside Whoop's Series G and Eight Sleep's Series D, India-based metabolic health wearable maker Ultrahuman secured the equivalent of about $44M in Series C funding in February 2026, and New Delhi-based Temple raised a $54M seed round the same month for a wearable focused on brain-centered health and performance, tracking cerebral blood flow through a proprietary measure the company calls Entropy, according to Crunchbase News.

Crunchbase's own predictive intelligence tools flag Whoop, Oura, Spring Health, and Fountain Life, which runs AI-driven longevity clinics, as the fitness and wellness sector's most likely IPO candidates, notably, none of them are pure hardware plays.

The compelling pitch in 2026 isn't a device that tracks something, it's a device that continuously collects health data and uses AI to turn it into personalized guidance, according to Crunchbase's own analysis of the funding pattern.

WHY IT MATTERS

Data and interpretation are the moat now, not the sensor

Sensors have become commoditized. Nearly every wearable on the market can measure heart rate, temperature, and motion to a similar standard. What separates a fundable fitness startup from an unfundable one in 2026 is what the company does with that data afterward, personalized coaching, predictive guidance, or a credible path to a clinical claim, not the hardware itself.

That's a meaningfully different pitch than the fitness startups of the 2010s, most of which competed on device design and accuracy alone. Temple's bet on a genuinely novel biomarker, cerebral blood flow, rather than yet another heart-rate or sleep metric, is a direct response to that commoditization: differentiate on what you measure, since how you measure it no longer is enough.

WORTH WATCHING

Whether novel biomarkers can find a real use case beyond curiosity

Watch whether Temple's cerebral blood flow metric, or similarly novel biomarkers from other well-funded entrants, translate into an actual behavior change or clinical use case, rather than becoming an interesting number with no clear action attached to it. A wearable that measures something new but can't tell the user what to do about it risks the same fate as early wearables that measured steps without ever proving steps alone changed anyone's health.

An AI-native biology startup just raised more in one seed round than most synthetic biology companies have raised in their entire lifetime

An AI-native biology startup just raised more in one seed round than most synthetic biology companies have raised in their entire lifetime

by | Aug 21, 2026 | Frontier Tech

EvolutionaryScale's $142M seed shows investors are starting to bet on AI models that design biology, not just companies that engineer it by hand.

Synthetic biology has spent years being an engineering-intensive, capital-intensive field. A new wave of AI-native entrants is testing whether that capital intensity can be front-loaded into a model instead.

WHAT HAPPENED

One seed round, bigger than most companies' entire funding history

EvolutionaryScale raised a $142M seed round, according to New Market Pitch's synthetic biology tracker, a round larger than the lifetime funding of many later-stage synthetic biology companies in the same dataset. The broader synthetic biology market has raised $9.1B across its top 60 ranked companies, per Seedtable, but most of that capital went to companies doing hands-on genetic engineering, precision fermentation, or cell programming, not AI models trained to design proteins computationally.

A related company, Pando, uses an AI-driven ultra-high-throughput screening platform that its founders say screens 1,000-fold more enzymes 75% faster and 80% cheaper than traditional methods, according to Y Combinator's portfolio listing, another example of the same underlying bet: that AI models can compress years of wet-lab iteration into a fraction of the time and cost.

Therapeutics-focused synthetic biology companies including Generate Biomedicines, ArsenalBio, Tessera, Senti Biosciences, and Obsidian Therapeutics have together raised about $3.2B, while food and materials-focused synthetic biology, Impossible Foods, Perfect Day, Solugen, Pivot Bio, and Motif FoodWorks, have raised roughly $4.5B combined, showing therapeutics is catching up fast to a category that used to be dominated by food and materials.

WHY IT MATTERS

A different capital efficiency story entirely

Traditional synthetic biology platforms need lab infrastructure, wet-lab scientists, and iterative testing cycles that take months per design. An AI-native approach front-loads that cost into training a model once, then running inference cheaply and quickly for every subsequent design. If that bet is right, it changes the unit economics of the entire category, and explains why a seed-stage AI biology company can raise more than an established synthetic biology platform with years of lab work behind it.

It's also a cautionary tale worth remembering: Amyris and Motif FoodWorks together absorbed about $1.5B in synthetic biology funding before shutting down, proof that capital alone doesn't solve the field's underlying scale-up risk, whether that capital comes from a lab-heavy platform or an AI-native one.

WORTH WATCHING

Whether the model-first bet actually ships products faster

Watch whether EvolutionaryScale and similar AI-native biology companies can convert their computational speed advantage into actual shipped products faster than traditional wet-lab platforms, since the real test isn't how fast a model can design a candidate, it's how fast that candidate survives real-world validation, manufacturing, and regulatory review, the same bottleneck that's already slowing down cell and gene therapy more broadly.

Cell and gene therapy has a manufacturing problem, and that’s where the funding is actually going

Cell and gene therapy has a manufacturing problem, and that’s where the funding is actually going

by | Aug 20, 2026 | Frontier Tech

The science of genetic medicine mostly works. Making enough of it, reliably, is the harder problem investors are now funding.

Cell and gene therapy has spent the last decade proving the science works. It's spent the last two years proving that manufacturing it at scale is the much harder, much less glamorous problem, and that's increasingly where the capital is concentrating.

WHAT HAPPENED

A manufacturing bottleneck becomes its own funding category

Cell and gene therapy platforms, including ElevateBio, Cellares, ArsenalBio, Kriya, AvenCell, Capstan, and Chime Biologics, have together raised roughly $4.2B, according to New Market Pitch's biotechnology funding tracker. Separately, Flagship Pioneering's newest venture, Serif Biomedicines, launched with $50M to develop what it calls "modified DNA" medicines, designed to combine the strengths of gene therapy, mRNA, and small-interfering RNA approaches in a single modality rather than picking one.

The federal government has also stepped in specifically on the manufacturing side. ARPA-H's new GIVE program is funding distributed, individualized biomanufacturing for genetic medicines, aiming to get a genetic treatment ready to dose within a week of diagnosis, a direct acknowledgment that centralized manufacturing is the actual chokepoint slowing the field down, not the underlying biology.

Gene editing companies rank second in biotechnology funding with $2.288B raised across just 17 deals, a 13.48% share of capital that shows sustained institutional interest even as the broader cell and gene therapy segment remains stuck near a multi-year funding plateau.

WHY IT MATTERS

The science outran the supply chain

For companies like ElevateBio and Cellares, the pitch isn't a new therapy, it's the infrastructure that lets other companies' therapies actually reach patients at scale. That's a meaningfully different, and arguably more durable, business than betting on any single genetic medicine's clinical trial outcome. It also explains why capital is flowing into "tools and platforms" alongside therapeutics themselves.

Cell and gene therapy makers overall are on pace to raise about $2 billion in 2026, similar to most years since 2022, according to BioPharma Dive, a multi-year plateau that stands in sharp contrast to the $13.168B flowing into therapeutics discovery platforms more broadly. The gap between "the science works" and "the manufacturing scales" is precisely where that plateau sits.

WORTH WATCHING

Whether ARPA-H's bet pays off before private capital loses patience

Watch whether ARPA-H's GIVE program produces a genuinely viable distributed manufacturing model, since that would be the clearest signal yet that the bottleneck is solvable rather than structural. Also watch whether Serif Biomedicines' "modified DNA" combination approach, betting that blending modalities beats picking one, becomes a template other well-funded platforms attempt to replicate, or whether it turns out combining approaches multiplies manufacturing complexity rather than solving it.

Parsley Health: The first functional medicine provider to go in-network nationwide

Parsley Health: The first functional medicine provider to go in-network nationwide

by | Aug 10, 2026 | Startups to Watch

A tenfold jump from New York-and-California coverage to an estimated 150 million insured Americans shows what happens when a "root cause" care model finally gets a payer contract to match its ambition.

Parsley Health delivers functional, root-cause primary care through a virtual-first membership, using dedicated care teams, deep lab panels, and longer visits to treat the drivers of chronic disease rather than the symptoms.

Functional medicine has had a devoted following for years, but almost entirely on a cash-pay basis, which capped its reach to patients who could afford to pay out of pocket for a slower, more investigative style of care. Parsley's expansion is a direct test of whether that model holds once insurance removes the affordability ceiling.

THE MODEL

Root cause over symptom management, backed by real time

Longer visits and deep lab panels are the operational commitment behind the "root cause" positioning, since functional medicine's core promise is meaningless without the time and testing budget to actually investigate underlying drivers rather than just treat presenting symptoms. Dedicated care teams reinforce that same commitment, giving patients continuity with the same clinicians across visits rather than a rotating cast, which matters for a model built around understanding a patient's health history in depth rather than addressing one complaint at a time.

Going in-network nationwide represents a tenfold jump in reachable insured population compared to Parsley's original New York and California coverage.

WHY IT MATTERS

Functional medicine's biggest historical barrier was payment, not philosophy

Functional medicine has had a devoted following for years, but almost entirely cash-pay, which capped its reach to patients who could afford to pay out of pocket. Parsley solving the insurance side of the equation is arguably a bigger deal than the clinical model itself, since it's the first mover to unlock this approach for a mainstream insured population at scale. That distinction matters because it shifts the competitive question from "does functional medicine work" to "can it work profitably inside an insurance model," a question the category hasn't had to answer at this scale before.

WORTH WATCHING

Whether outcomes data keeps pace with payer trust

Watch whether Parsley publishes outcomes data at the same pace its payer network grows, since sustained in-network status usually depends on proving the root-cause approach reduces downstream costs, not just on signing the initial contracts. Payers extend trust based on early results, then expect that trust to be continually re-earned with real outcomes data as the population being served grows larger and more varied. Whether Parsley's model holds up across that broader, more diverse insured population the way it did in its original two-state base is the open question worth tracking.

Visit Website
Maven Clinic: Turning an underfunded category into enterprise-grade benefits

Maven Clinic: Turning an underfunded category into enterprise-grade benefits

by | Aug 10, 2026 | Startups to Watch

The largest virtual clinic for women's and family health, spanning fertility, maternity, and menopause, shows what it looks like when a single platform becomes the default employer benefit for an entire life stage category.

Maven Clinic is the largest virtual clinic for women's and family health, spanning fertility, maternity, and menopause. Employer benefits in this space have historically been assembled piecemeal, a fertility vendor here, a maternity program there, menopause support added later if at all, each requiring its own vendor relationship, its own contract negotiation, and its own integration into benefits enrollment. Maven's scale comes from collapsing that fragmented buying process into one relationship.

THE MODEL

One platform, one employer contract, three life stages

Rather than requiring an employer to source separate fertility, maternity, and menopause benefits from different vendors, Maven consolidates all three into one enterprise contract, which is a meaningfully easier sell to a benefits team managing dozens of point solutions. A single point of contact, a single contract renewal cycle, and a single data integration into the employer's broader benefits stack is a substantial administrative simplification compared to managing three or four separate vendor relationships across a woman's reproductive and midlife journey.

Women's and family health benefits have historically been treated as a collection of disconnected point solutions rather than a single coordinated benefit category, which is exactly the fragmentation Maven's model eliminates.

WHY IT MATTERS

Consolidation is the enterprise unlock

Benefits leaders are increasingly fatigued by managing dozens of narrow point-solution vendors. A platform spanning fertility through menopause under one contract is a structural advantage in enterprise sales that a single-condition competitor can't easily match. That consolidation advantage compounds over time too, since an employer already running Maven for fertility has a much lower switching cost to add menopause support through the same platform than to onboard an entirely new, unrelated vendor.

WORTH WATCHING

Whether breadth stays ahead of specialist depth

Watch whether specialist single-condition competitors, in menopause or fertility specifically, can out-compete Maven on depth of care within their narrower lane, even as Maven continues to win on breadth and consolidation at the employer level. A specialist competitor's pitch is usually that depth beats breadth for any single condition, so the real test is whether Maven's scale lets it match that depth condition-by-condition, or whether benefits leaders eventually have to choose between one consolidated, slightly shallower vendor and several deeper, harder-to-manage specialist ones.

Visit Website